Synopsis:- In a regulatory win that expands its US injectable footprint, Caplin Point Laboratories’ subsidiary Caplin Steriles has received final USFDA approval for Calcium Gluconate Injection USP across three vial sizes, targeting a market worth approximately $71 million in annual US sales, the 54th ANDA approval for the subsidiary.
Shares of a leading pharma company focused on emerging markets and regulated injectables came into focus after its US-facing subsidiary received a fresh USFDA final approval. The approval, filed as an Abbreviated New Drug Application (ANDA), covers a generic therapeutic equivalent of a Fresenius Kabi USA product in a market with over $71 million in annual US sales as of March 2026.
With a market capitalization of Rs. 13,473.07 crore, the shares of Caplin Point Laboratories were trading at Rs. 1,772.5 per share, up 2.08 percent from its previous closing price of Rs. 1,736 apiece. It is trading at a P/E of 21.22.
Caplin Steriles Limited (CSL), the sterile injectables subsidiary of Caplin Point Laboratories, has received final approval from the USFDA for Calcium Gluconate Injection USP at 100 mg/mL, available in 10 mL, 50 mL, and 100 mL vials.
The drug is indicated for both pediatric and adult patients experiencing acute symptomatic hypocalcemia and is a generic equivalent of Fresenius Kabi USA’s reference listed drug under NDA 208418. According to IQVIA data cited in the filing, the three pack-size combination had US sales of approximately $71 million for the twelve months ending March 2026, giving CSL a tangible revenue opportunity to target in the near term.
This approval marks CSL’s 54th ANDA clearance in the US, counting both self-filed and acquired ANDAs, a number that places the subsidiary among the more productive sterile injectable filers among mid-cap Indian pharma companies. CSL currently holds approvals from the USFDA, EU-GMP, ANVISA (Brazil), and INVIMA (Colombia), covering multiple regulated and semi-regulated markets.
Beyond the existing approved portfolio, CSL has a pipeline of 55-plus simple and complex injectable and ophthalmic products earmarked for filing over the next four years. A separate subsidiary, Caplin One Labs (COL), has five approved ANDAs for injectable products, with its oncology unit at Kakkalur now into its second year of operations. The breadth of the combined filing pipeline gives the group reasonable revenue runway from US approvals alone, though execution and pricing dynamics in generics remain variables to watch.
Business Overview
Caplin Point Laboratories manufactures and markets pharmaceutical products predominantly in Latin America and Africa, while CSL handles regulated market filings. For the quarter ended December 2025, the company reported consolidated revenues of Rs. 543 crore and a net profit of Rs. 166 crore, continuing a steady trajectory of quarterly earnings growth. Operating profit margins held at 35 percent, consistent with the prior two quarters.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
